Interim data suggest long-term treatment improves generalized myasthenia gravis disease scores
Argenx SE, a Belgian drug maker, recently announced interim results from ADAPT+, an ongoing Phase 3, open-label, three-year extension study evaluating long-term safety, tolerability and efficacy of VYVGART (efgartigimod alfa-fcab) ...